Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:797914.
doi: 10.1155/2013/797914. Epub 2013 Nov 18.

The role of s-nitrosylation and s-glutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration

Affiliations
Review

The role of s-nitrosylation and s-glutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration

M Halloran et al. Int J Cell Biol. 2013.

Abstract

Neurodegenerative diseases involve the progressive loss of neurons, and a pathological hallmark is the presence of abnormal inclusions containing misfolded proteins. Although the precise molecular mechanisms triggering neurodegeneration remain unclear, endoplasmic reticulum (ER) stress, elevated oxidative and nitrosative stress, and protein misfolding are important features in pathogenesis. Protein disulphide isomerase (PDI) is the prototype of a family of molecular chaperones and foldases upregulated during ER stress that are increasingly implicated in neurodegenerative diseases. PDI catalyzes the rearrangement and formation of disulphide bonds, thus facilitating protein folding, and in neurodegeneration may act to ameliorate the burden of protein misfolding. However, an aberrant posttranslational modification of PDI, S-nitrosylation, inhibits its protective function in these conditions. S-nitrosylation is a redox-mediated modification that regulates protein function by covalent addition of nitric oxide- (NO-) containing groups to cysteine residues. Here, we discuss the evidence for abnormal S-nitrosylation of PDI (SNO-PDI) in neurodegeneration and how this may be linked to another aberrant modification of PDI, S-glutathionylation. Understanding the role of aberrant S-nitrosylation/S-glutathionylation of PDI in the pathogenesis of neurodegenerative diseases may provide insights into novel therapeutic interventions in the future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Domains of PDIA1. TRX-like domains representing catalytic active domains a a′. The b domain and b′ are catalytically inactive. The linker region is responsible for binding to the substrate. The C terminal is followed by an ER retrieval signal KDEL.
Figure 2
Figure 2
Cell surface PDI, NO, and SNO-PDI. (A) Cell surface PDI reduces NO from extracellular SNO proteins (SNO-P) and in the process undergoes thiol modification. (B) Hyperactivation of the NMDAr leads to an intracellular influx of Ca2+ ions (NMDAr may also undergo reversible S-nitrosylation to ameliorate excessive activity). (C) Inhibition of mitochondria contributes to an increase in intracellular NO which is potentially oxidized by O2 leading to an increase in NO, nNOS, ROS, and RNS. (D) Increases in RNS/ROS alters the ER redox environment, and NO S-nitrosylates Ca2+ ryanodine (Ryn) receptor leading to a disruption in Ca2+ homeostasis. (E) ER-resident proteins such as PDI are vulnerable to S-nitrosylation, deactivating its isomerase and chaperone activity, leading to accumulation of misfolded proteins, ER stress, and UPR induction.
Figure 3
Figure 3
S-glutathionylation of PDI. Nitrosative stress from an exogenous agent (PABA/NO) increases intracellular NO and leads to the production of SNO-PDI. However, this may result in a decrease in GSSG/GSH ratio and increases in the free cellular pool of GSH. GSH then binds to the catalytic (a, a′) domains of PDI, resulting in S-glutathionylation (P-SSG) of its cysteine residues and attenuation of its protective isomerase and chaperone activity.

References

    1. Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. American Journal of Neurodegenerative Disease. 2013;2(1):1–14. - PMC - PubMed
    1. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience. 2003;4(1):49–60. - PubMed
    1. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochemical and Biophysical Research Communications. 2012;425(3):534–539. - PubMed
    1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(13):44913–4917. - PMC - PubMed
    1. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies. Nature. 1997;388(6645):839–840. - PubMed

LinkOut - more resources